Izračunajte točne volumene rekonstitucije, inzulinske jedinice i doze po bočici za svaki peptid.
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found at high concentrations in virtually every cell of the human body. The TB-500 designation refers specifically to a 17-amino-acid fragment corresponding to the actin-binding domain of full-length Thymosin Beta-4 (residues 17–23 in the native protein, often referred to as the LKKTETQ sequence). This fragment retains the full biological activity of the parent molecule while being smaller, more synthesizable, and more economically viable for research applications.
Thymosin Beta-4 was originally identified as a thymic hormone involved in T-cell maturation, but subsequent research revealed its primary biological function to be the sequestration and regulation of actin — one of the most abundant proteins in eukaryotic cells and the principal structural component of the cytoskeleton. By binding G-actin monomers and preventing their polymerization into F-actin filaments, Thymosin Beta-4 controls cell shape, motility, and the wound-healing response at the cellular level.
The breadth of TB-500's preclinical evidence is impressive: it has been studied in models of myocardial infarction, stroke, skeletal muscle injury, tendon damage, peripheral nerve injury, corneal healing, and dermal wound closure. It is also one of the most studied peptides for hair follicle biology, with evidence suggesting it can reactivate dormant follicles and accelerate hair shaft elongation. TB-500 does not affect sex hormones, does not suppress the hypothalamic-pituitary axis, and has no known interaction with endocrine systems — making it one of the safer peptides for both male and female research applications.
TB-500 operates through several distinct and interrelated mechanisms:
TB-500 is administered at significantly higher doses than many other research peptides because it works through receptor-mediated mechanisms requiring a threshold tissue concentration. It does not require titration, though starting at the lower end of the range is advisable for new users.
Adding 2 mL of bacteriostatic water to a standard 5 mg vial yields a concentration of 2.5 mg/mL.
At the standard 2.5 mg dose administered 2 times per week, one 5 mg vial provides exactly 2 injections. A 10 mg vial at the same protocol provides 4 injections (2 weeks of dosing). Use the TB-500 calculator above to compute volumes for any vial size, reconstitution volume, and target dose.
TB-500 protocols often follow a loading and maintenance phase structure:
TB-500 is supplied as a lyophilized powder in sealed vials and must be reconstituted with bacteriostatic water before injection. Use bacteriostatic water — not sterile water or saline — for multi-dose vials, as its benzyl alcohol content inhibits microbial growth and extends the shelf life of the reconstituted solution.
Discard any vial where the reconstituted solution is cloudy, discolored, or contains visible particles. Never inject a solution that does not appear fully clear.
TB-500 has a favorable safety profile in preclinical research. It is a fragment of an endogenous human protein, and no organ toxicity, mutagenicity, or significant immune reactions have been documented in animal studies at research doses. Human clinical data is limited, consistent with most research peptides.
The combination of TB-500 with BPC-157 is the premier tissue-repair stack in peptide research, often called the Healing Stack. The two peptides work through distinct pathways that create a powerful synergy:
Healing Stack protocol: TB-500 2.5 mg, 2–3x per week + BPC-157 250–500 mcg daily, both subcutaneous, for 4–8 weeks. View the BPC-157 calculator for BPC-157 dosing details.
For comprehensive soft tissue and skin repair — particularly relevant after surgery, burns, or chronic wounds — combining TB-500 with GHK-Cu adds the copper peptide's collagen synthesis stimulation and antioxidant gene modulation to TB-500's cell migration and vascular effects. This combination is particularly suited to users with skin or hair restoration goals alongside systemic tissue repair objectives.
TB-500 has the most extensive evidence base for cardiac tissue repair of any peptide in research. Studies in myocardial infarction models demonstrate that TB-500 significantly reduces infarct size, improves ventricular function, promotes cardiomyocyte survival, and stimulates new vessel formation in ischemic zones. For neural recovery applications, preclinical evidence shows improved outcomes after traumatic brain injury and peripheral nerve crush models. These are among the most compelling potential applications for TB-500 and the primary reason it attracts interest beyond musculoskeletal use.
You can purchase research-grade TB-500 from BergdorfBio: TB-500 at BergdorfBio.
TB-500 is a 17-amino-acid fragment corresponding to the actin-binding domain of full-length Thymosin Beta-4 (a 43-amino-acid protein). Research has shown that this fragment retains the majority of the parent molecule's biological activity, particularly for wound healing and angiogenesis. TB-500 is more economically synthesizable and has better characterized pharmacokinetics, making it the preferred form for research applications. The two should not be considered identical, however — full-length Tβ4 has additional signaling properties beyond the actin-binding domain.
TB-500 operates through mechanisms that require a higher tissue concentration to achieve threshold biological activity. Its actin-sequestration function involves stoichiometric binding to actin monomers — a high-abundance cellular target that demands correspondingly higher peptide concentrations. BPC-157, by contrast, acts through receptor-mediated signaling cascades where even nanomolar concentrations can trigger substantial cellular responses.
TB-500 has a half-life of approximately 7 days in the body, significantly longer than most research peptides. This extended activity window explains why 2–3 injections per week — rather than daily dosing — are sufficient for therapeutic tissue concentrations. After the last injection in a cycle, biologically active concentrations persist for 1–2 weeks as the peptide slowly clears.
Preclinical evidence is supportive. Thymosin Beta-4 is expressed in hair follicle outer root sheath cells and has been shown to activate hair follicle stem cells, promote anagen (growth phase) maintenance, and stimulate hair shaft elongation in animal models. The relevance to human androgenic alopecia or telogen effluvium has not been established in clinical trials. Some users report improved hair density and reduced shedding after TB-500 cycles, but individual results vary considerably.
No direct anabolic (muscle-building) or lipolytic (fat-burning) activity has been attributed to TB-500. It does not stimulate GH or IGF-1 production. Any improvements in body composition observed during TB-500 use are typically secondary effects of faster injury recovery enabling more consistent training, rather than a direct pharmacological action on muscle or fat tissue.
TB-500 is prohibited under WADA regulations as a peptide hormone and growth factor. Detection methods exist in anti-doping laboratories and have been validated to identify TB-500 use. Athletes subject to WADA-compliant testing should treat TB-500 as a prohibited substance at all times, including during the off-season.
Long-term continuous use is not recommended given the absence of chronic human safety data. Most practitioners use cycle lengths of 8–12 weeks with 4-week breaks. Continuous use beyond 3 months is not well characterized in any published research, and the long half-life means that concentrations accumulate over repeated dosing — making off-periods particularly important for TB-500 relative to shorter-lived peptides.
Because standard TB-500 doses at 2.5 mg/mL concentration require 1.0 mL of solution per injection, a 1.0 mL (100-unit) insulin syringe is the appropriate size. A 0.3 mL or 0.5 mL syringe is not practical at the standard dose because it cannot hold the full injection volume. A 27–29 gauge, 12 mm needle is suitable for subcutaneous injection at this volume.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. TB-500 is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.
Pogledajte proizvod
TB-500